{
  "abstract": "Limited treatment options and therapy resistance make pancreatic ductal adenocarcinoma (PDAC) one of the cancer types with the poorest prognosis and survival rates.1 Currently, the standard of care for PDAC primarily involves chemotherapy, and immunotherapy has yet to show significant benefits in this context.2",
  "authors": [
    {
      "affiliations": [
        "Cancer Immunity Laboratory. Molecular Oncology Programme, Centro Nacional de Investigaciones Oncologicas Carlos III, Madrid, Spain"
      ],
      "name": "Eduardo Garvin-Jiménez"
    },
    {
      "affiliations": [
        "Cancer Immunity Laboratory. Molecular Oncology Programme, Centro Nacional de Investigaciones Oncologicas Carlos III, Madrid, Spain"
      ],
      "name": "María Casanova-Acebes"
    }
  ],
  "title": "It takes two to TAM-go",
  "uid": "6b296817-2f3e-5f30-ae03-5e1a62838b2c"
}